Research programme: receptor tyrosine kinase inhibitors - GlaxoSmithKlineAlternative Names: REarranged in Transfection tyrosine kinase inhibitors; GSK 1838705A; GW-578257A; RET inhibitors; RET tyrosine kinase inhibitors; VEGFR-2/TIE-2 inhibitors - GSK
Latest Information Update: 18 Apr 2011
At a glance
- Originator GlaxoSmithKline
- Class Benzimidazoles; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Insulin-like growth factor-I receptor antagonists; Receptor protein-tyrosine kinase antagonists; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer